Alkermes plc. Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax
Alkermes plc. (ALKS) reported Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax of -$15.30 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-02-24.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax · last filed 2015-02-24
- Alkermes plc. other comprehensive income (loss), reclassification adjustment from aoci for sale of securities, tax for the quarter ending 2014-12-31 was $0.00.
- Alkermes plc. other comprehensive income (loss), reclassification adjustment from aoci for sale of securities, tax for the quarter ending 2014-09-30 was $0.00.
- Alkermes plc. other comprehensive income (loss), reclassification adjustment from aoci for sale of securities, tax for the quarter ending 2014-06-30 was -$15.30M.
- Alkermes plc. other comprehensive income (loss), reclassification adjustment from aoci for sale of securities, tax for the quarter ending 2014-03-31 was $0.00.
- Alkermes plc. other comprehensive income (loss), reclassification adjustment from aoci for sale of securities, tax for fiscal 2014 was -$15.30M.
- Alkermes plc. other comprehensive income (loss), reclassification adjustment from aoci for sale of securities, tax for fiscal 2013 was -$1.03M.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax 3 month | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax 6 month | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax 9 month | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax 12 month |
|---|---|---|---|---|
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $0.00 derived: sum of 2 quarters · filed 2015-02-24 | -$15.30M derived: sum of 3 quarters · filed 2015-02-24 | -$15.30M 10-K · filed 2015-02-24 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-29 | -$15.30M derived: sum of 2 quarters · filed 2014-10-29 | -$15.30M 10-Q · filed 2014-10-29 | |
| 2014-06-30 | -$15.30M 10-Q · filed 2014-07-31 | -$15.30M 10-Q · filed 2014-07-31 | ||
| 2014-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2015-02-24 | |||
| 2013-03-31 | -$1.03M 10-K · filed 2015-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |